Quadria Capital preparing to exit biotech firm

By Ranjani Raghavan

  • 21 Apr 2021
Premium
Credit: Pexels

India and Southeast Asia-focused Quadria Capital is preparing to exit a biotech portfolio firm as deals in the broader pharmaceuticals space gain traction because of the pandemic.    Quadria Capital is preparing to exit its 20% stake in Concord Biotech and has shortlisted Kotak Mahindra Bank and Torreya Partners to run ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.